Acetyl transferase EP300 deficiency leads to chronic replication stress mediated by defective fork protection at stalled replication forks

Angelica Barreto-Galvez, Mrunmai Niljikar, Julia Gagliardi, Ranran Zhang, Vasudha Kumar, Aastha Juruwala, Archana Pradeep, Anam Shaikh, Priyanka Tiwari, Kritika Sharma, Jeannine Gerhardt, Jian Cao, Keisuke Kataoka, Adam D. Durbin, Jun Qi, B. Hilda Ye, Advaitha MadireddybioRxiv 2023 · DOI

TL;DR

Mutations in the EP300 gene, a key epigenetic regulator, are linked to aggressive blood cancers. This study reveals that EP300 deficiency cripples DNA replication fork stability, leading to widespread genomic instability and a cellular environment ripe for cancer development. This work highlights EP300's crucial, previously unrecognized role in maintaining genome integrity.

What Problem Does This Paper Address?

Aggressive hematological malignancies, like adult T-cell leukemia/lymphoma (ATLL), are increasingly associated with mutations in EP300, a gene encoding a crucial epigenetic regulator and transcriptional coactivator. However, the precise mechanisms by which EP300 loss contributes to cancer initiation and progression have remained unclear. While EP300 is known to influence cell cycle and DNA damage response genes, its specific role in the intricate process of DNA replication, particularly at the critical replication fork, was not well understood. This paper aims to elucidate EP300's function in maintaining DNA replication integrity and how its deficiency leads to genomic instability, a hallmark of cancer.

Methods

The researchers employed a multi-pronged approach using patient-derived ATLL cell lines with and without EP300 mutations, as well as a selective EP300 degrader (PROTAC) to mimic EP300 deficiency. Key techniques included:

  • Western blotting: To assess protein expression levels of key players in DNA replication, repair, and cell cycle control, including H3K27ac (a marker of transcriptional regulation), p300, phospho-Chk1, phospho-RPA, γH2AX, BRCA1, BRCA2, RAD51, and POLD3.
  • Cell doubling time analysis: To measure the rate of cell proliferation and identify cell cycle delays.
  • Comet assay: To quantify DNA breaks and assess overall genomic instability.
  • Immunofluorescence microscopy: To visualize and quantify protein localization and DNA damage markers (e.g., γH2AX foci, ssDNA gaps, RPA phosphorylation, RAD51 foci, BRCA1/2 foci, POLD3 foci, FANCD2 foci, 53BP1 nuclear bodies) within cells.
  • Single Molecule Analysis of Replicated DNA (SMARD): A sophisticated technique to visualize and analyze DNA replication dynamics at specific genomic loci (common fragile sites like FRA6E), tracking replication fork progression and origin firing.
  • DNA fiber analysis: To assess genome-wide replication fork stalling and nucleolytic degradation of nascent DNA.
  • Mitotic DNA Synthesis (MiDAS) analysis: To investigate DNA replication occurring during mitosis, particularly at under-replicated regions.

The use of a selective EP300 PROTAC degrader (JQAD1) was a key methodological advantage, allowing for precise and reversible inhibition of EP300 without affecting its paralog CBP, thus enabling direct assessment of EP300's specific role.

Datasets

Not discussed in the paper. The study primarily utilizes established human cell lines and patient-derived cell lines.

Key Insights and Ideas

  • EP300 deficiency fuels replication stress: Even in the absence of external DNA damaging agents, EP300-mutated cells exhibit significant endogenous replication stress, characterized by increased origin firing and replisome pausing.
  • Replication fork protection is compromised: EP300 deficiency leads to a critical failure in stabilizing stalled replication forks, resulting in nucleolytic degradation of nascent DNA. This is a major departure from normal cellular processes where such forks are protected.
  • BRCA2 is a key downstream effector: The study identifies a significant downregulation of BRCA2 protein expression in EP300-deficient cells, suggesting that EP300 is essential for maintaining BRCA2 levels, which are critical for fork stability.
  • Shift towards error-prone repair: With defective fork protection, EP300-mutated cells become heavily reliant on error-prone repair mechanisms, specifically POLD3-mediated restart pathways, which are characteristic of BRCA-deficient cancers.
  • Inherited damage and cytosolic DNA: The unresolved DNA damage in EP300-deficient cells is not only passed on to daughter cells but also leads to the accumulation of toxic cytosolic DNA, further contributing to genomic instability.
  • Mimicking BRCA-deficient cancers: The overall phenotype of EP300-deficient ATLL cells closely mirrors that of BRCA-deficient cancers, highlighting a shared vulnerability and a potential therapeutic avenue.

Key Results

  • EP300-mutated cells exhibit prolonged cell cycle kinetics and increased genomic instability, evidenced by elevated γH2AX foci and DNA breaks.
  • Replication in EP300-mutated cells is characterized by increased origin firing and replisome pausing, particularly at common fragile sites.
  • There is a significant increase in nucleolytic degradation of nascent DNA at stalled forks in EP300-deficient cells, which is rescued by Mre11 inhibition.
  • EP300 deficiency leads to decreased BRCA2 protein expression.
  • EP300-mutated cells show increased reliance on POLD3 for replication restart.
  • Under-replicated DNA in G2/M leads to mitotic DNA synthesis (MiDAS), resulting in mitotic segregation defects, micronuclei formation, and accumulation of cytosolic DNA.

Limitations and Future Work

  • Downregulation mechanism of BRCA2: The study identifies BRCA2 downregulation as a key consequence of EP300 deficiency but notes that the precise mechanisms underlying this downregulation require further investigation.
  • Therapeutic implications: While the study highlights similarities to BRCA-deficient cancers, further research is needed to explore targeted therapeutic strategies for EP300-mutated cancers, potentially leveraging synthetic lethality approaches.
  • Broader cancer relevance: While focused on ATLL, future work could explore whether these findings extend to other EP300-mutated cancers.
  • In vivo validation: While a PROTAC degrader with limited toxicity was used, further in vivo studies would be beneficial to fully validate the findings and assess therapeutic potential.

Summary updated

Abstract

Abstract Mutations in the epigenetic regulator and global transcriptional activator, E1A binding protein (EP300), is being increasingly reported in aggressive hematological malignancies including adult T-cell leukemia/lymphoma (ATLL). However, the mechanistic contribution of EP300 dysregulation to cancer initiation and progression are currently unknown. Independent inhibition of EP300 in human cells results in the differential expression of genes involved in regulating the cell cycle, DNA replication and DNA damage response. Nevertheless, specific function played by EP300 in DNA replication initiation, progression and replication fork integrity has not been studied. Here, using ATLL cells as a model to study EP300 deficiency and an p300-selective PROTAC degrader, degrader as a pharmacologic tool, we reveal that EP300-mutated cells display prolonged cell cycle kinetics, due to pronounced dysregulations in DNA replication dynamics leading to persistent genomic instability. Aberrant DNA replication in EP300-mutated cells is characterized by elevated replication origin firing due to increased replisome pausing genome-wide. We demonstrate that EP300 deficiency results in nucleolytic degradation of nascently synthesized DNA at stalled forks due to a prominent defect in fork stabilization and protection. This in turn results in the accumulation of single stranded DNA gaps at collapsed replication forks, in EP300-deficient cells. Inhibition of Mre11 nuclease rescues the ssDNA accumulation indicating a dysregulation in downstream mechanisms that restrain nuclease activity at stalled forks. Importantly, we find that the absence of EP300 results in decreased expression of BRCA2 protein expression and a dependency on POLD3-mediated error-prone replication restart mechanisms. The overall S-phase abnormalities observed lead to under-replicated DNA in G2/M that instigates mitotic DNA synthesis. This in turn is associated with mitotic segregation defects characterized by elevated micronuclei formation, accumulation of cytosolic DNA and transmission of unrepaired inherited DNA lesions in the subsequent G1-phase in EP300-deficient cells. We demonstrate that the DNA replication dynamics of EP300-mutated cells ATLL cells recapitulate features of BRCA-deficient cancers. Altogether these results suggest that mutations in EP300 cause chronic DNA replication stress and defective replication fork restart results in persistent genomic instability that underlie aggressive chemo-resistant tumorigenesis in humans.
BibTeX
@misc{barretogalvez2023acetyl,
  author = {Angelica Barreto-Galvez and Mrunmai Niljikar and Julia Gagliardi and Ranran Zhang and Vasudha Kumar and Aastha Juruwala and Archana Pradeep and Anam Shaikh and Priyanka Tiwari and Kritika Sharma and Jeannine Gerhardt and Jian Cao and Keisuke Kataoka and Adam D. Durbin and Jun Qi and B. Hilda Ye and Advaitha Madireddy},
  title = {{Acetyl transferase EP300 deficiency leads to chronic replication stress mediated by defective fork protection at stalled replication forks}},
  year = {2023},
  doi = {10.1101/2023.04.29.538781},
  howpublished = {bioRxiv},
}
Figure